---
title: "Ketamine Reduces In Vitro Immune Sensitization in Major Depressive Disorder in a Concentration-Dep"
id: "medrxiv-10-in-vitro-ketamine-attenuates-immune-sensitization-in-major-depressive-disorder"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-10-in-vitro-ketamine-attenuates-immune-sensitization-in-major-depressive-disorder"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.28.26361493v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Ketamine Reduces In Vitro Immune Sensitization in Major Depressive Disorder in a Concentration-Dep
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-10-in-vitro-ketamine-attenuates-immune-sensitization-in-major-depressive-disorder
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.28.26361493v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This ex vivo study tested whether **ketamine** reduces stimulus-induced immune sensitization in patients with **major depressive disorder (MDD)** versus healthy controls (HCs). Whole blood from 18 MDD patients and 18 HCs was stimulated with **PHA/LPS** and exposed to ketamine at 0.3 μM, 0.6 μM, and 6 μM for 72 hours. Cytokines, chemokines, growth factors, and composite immune profiles (M1/M2, Th1/Th2/Th17, IRS, CIRS) were measured. - Under PHA/LPS stimulation, the MDD group showed broadly elevated immune profiles—M1, M2, Th1, Th2, Th17, IRS, CIRS, chemokines, and growth factors—consistent with an immune-sensitized phenotype. - Significant group-by-treatment interactions were reported for several composite and individual measures: Th1–Th2 balance, M2, growth factors, IL-12(p70), M1, and chemokines, indicating differing ketamine effects in MDD versus HCs. - Ketamine produced minimal effects in HCs but caused broader suppression of stimulated immune responses in the MDD group, especially at the highest concentration (6 μM); however, it did not fully normalize the sensitized immune phenotype in MDD. - Several immune markers showed diagnosis-independent reductions with ketamine (reduced across both groups): MIP-1β, IL-1β, Th1, TNF-β, IRS, IFN-γ, and IL-2 compared with control conditions. - The authors conclude ketamine demonstrates two immunoregulatory patterns: selective, disease-dependent attenuation of sensitized pathways and broader, diagnosis-independent suppression at higher concentrations; nevertheless, these effects were not sufficient to restore the MDD immune phenotype to control levels. - Study approvals and informed consent were obtained; data are available from the corresponding author on request. The authors declared no competing interests.
## Clinical Analysis & Structured Key Points
In Vitro Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner | medRxiv Skip to main content In Vitro Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner View ORCID Profile Yingqian Zhang , Xiaoman Zhuang , Mengqi Niu , Tangcong Chen , Yueyang Luo , Yiping Luo , View ORCID Profile Abbas F. Almulla , Andre F Carvalho , View ORCID Profile Michael Maes , Jing Li doi: https://doi.org/10.64898/2026.08.28.26361493 Yingqian Zhang 1 University of Electronic Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Yingqian Zhang Xiaoman Zhuang 2 The First Affiliated Hospital of Chongqing Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mengqi Niu 1 University of Electronic Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tangcong Chen 1 University of Electronic Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yueyang Luo 1 University of Electronic Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yiping Luo 1 University of Electronic Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abbas F. Almulla 1 University of Electronic Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Abbas F. Almulla Andre F Carvalho 3 Deakin University Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael Maes 1 University of Electronic Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Michael Maes For correspondence: michaelmaes{at}uestc.edu.cn Jing Li 1 University of Electronic Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract Background: Major depressive disorder (MDD) is a severe mental illness associated with severe clinical consequences and substantial societal burden. It's characterized by immune-inflammatory dysregulation and immune sensitization. Objective: To determine whether in vitro ketamine attenuates phytohemagglutinin (PHA)/lipopolysaccharide (LPS)-induced immune sensitization in patients with MDD and healthy controls (HCs). Methods: Whole blood from 18 patients with MDD and 18 HCs was stimulated with PHA/LPS and exposed to ketamine (0.3 μM, 0.6 μM, and 6 μM) for 72 hours. Cytokines, chemokines, growth factors, and composite immune profiles, including M1/M2 macrophages, T helper (Th)1/2/17, the immune-inflammatory response system (IRS), and compensatory immunoregulatory system (CIRS), were synthesized and determined. Results: Under PHA and LPS stimulation in vitro, the MDD group exhibited markedly elevated immune profiles, including M1, M2, Th1, Th2, Th17, IRS, CIRS, chemokines, and growth factors, consistent with immune sensitization. Significant group-by-treatment interactions were observed for Th1-Th2, M2, growth factors, IL-12(p70), M1, and chemokines. Ketamine produced minimal changes in HCs but broader suppression in MDD, particularly at the highest concentration, without normalizing the sensitized immune phenotype. Among the immune markers with no notable group-by-treatment interactions, ketamine exerted diagnosis-independent effects, decreasing MIP-1β, IL-1&β, Th1, TNF-β IRS, IFN-γ, and IL-2 compared to the control condition. Conclusions: Ketamine exhibited two distinct immunoregulatory patterns: selective, disease-dependent attenuation of sensitized immune pathways and broader, diagnosis-independent suppression of the stimulated immune response, predominantly at higher concentrations. However, these effects were insufficient to normalize the immune-sensitized phenotype of MDD. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Ethics Committee of the University of Electronic Science and Technology of China (Approval No.: 30005). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data will be provided by the corresponding author (Michael Maes) upon request. Funder Information Declared Science and Technology Department of Sichuan Province, https://ror.org/04323m874 , 2025HJPJ0004 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following In Vitro Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share In Vitro Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner Yingqian Zhang , Xiaoman Zhuang , Mengqi Niu , Tangcong Chen , Yueyang Luo , Yiping Luo , Abbas F. Almulla , Andre F Carvalho , Michael Maes , Jing Li medRxiv 2026.08.28.26361493; doi: https://doi.org/10.64898/2026.08.28.26361493 Share This Article: Copy Citation Tools In Vitro Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner Yingqian Zhang , Xiaoman Zhuang , Mengqi Niu , Tangcong Chen , Yueyang Luo , Yiping Luo , Abbas F. Almulla , Andre F Carvalho , Michael Maes , Jing Li medRxiv 2026.08.28.26361493; doi: https://doi.org/10.64898/2026.08.28.26361493 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (896) Anesthesia (326) Cardiovascular Medicine (4770) Dentistry and Oral Medicine (474) Dermatology (407) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1614) Epidemiology (15835) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6983) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4982) Health Policy (1426) Health Systems and Quality Improvement (1736) Hematology (581) HIV/AIDS (1336) Infectious Diseases (except HIV/AIDS) (16244) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (720) Neurology (7194) Nursing (363) Nutrition (1074) Obstetrics and Gynecology (1231) Occupational and Environmental Health (1001) Oncology (3573) Ophthalmology (1036) Orthopedics (393) Otolaryngology (446) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1772) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5832) Public and Global Health (9691) Radiology and Imaging (2387) Rehabilitation Medicine and Physical Therapy (1432) Respiratory Medicine (1241) Rheumatology (633) Sexual and Reproductive Health (766) Sports Medicine (576) Surgery (766) Toxicology (107) Transplantation (303) Urology (286)
## Related Clinical Research

- [Adverse Pregnancy Outcomes as Predictors of Long-Term Cardiovascular Disease Risk](https://medichelpline.com/clinical-feed/pubmed-42669304.md) (DOI: 10.1016/S0140-6736(26)01235-3)
- [Subjective Oral Status, Oral Health Behaviours, and History of Systemic Disease in Older Adults](https://medichelpline.com/clinical-feed/pubmed-42694012.md) (DOI: 10.3290/j.ohpd.c_2807)
- [Atomoxetine and Stimulant Use in Pregnancy: Maternal and Birth Outcome Findings](https://medichelpline.com/clinical-feed/womens-mental-health-0-atomoxetine-and-stimulants-during-pregnancy-what-do-we-know-about-pregnancy.md)
- [Most-favored nation pharma deals target Medicaid but exempt Medicare, analysts say](https://medichelpline.com/clinical-feed/stat-news-0-stat-how-trump-s-latest-pharma-deals-may-undermine-efforts-to-rein-in-drug-costs.md)
- [Analysis: Five key questions about Trump’s latest drugmaker deals and what's still unknown](https://medichelpline.com/clinical-feed/stat-news-0-stat-5-burning-questions-on-trump-s-latest-deals-with-drugmakers.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.